323 related articles for article (PubMed ID: 26945054)
21. Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy.
Friedl C; Zitt E
Drug Des Devel Ther; 2018; 12():1589-1598. PubMed ID: 29910605
[TBL] [Abstract][Full Text] [Related]
22. The effects of cinacalcet treatment on bone mineral metabolism, anemia parameters, left ventricular mass index and parathyroid gland volume in hemodialysis patients with severe secondary hyperparathyroidism.
Torun D; Yildiz I; Micozkadioglu H; Nursal GN; Yigit F; Ozelsancak R
Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):15-22. PubMed ID: 26787561
[TBL] [Abstract][Full Text] [Related]
23. Compliance with objectives based on different guidelines (KDIGO/S.E.N.) and analysis of the individual variability of mineral metabolism in haemodialysis patients in the medium term.
del Pozo-Fernández C; López-Menchero-Martínez R; Álvarez-Avellán L; Albero-Molina MD; Sánchez-Rodríguez L
Nefrologia; 2013; 33(5):675-84. PubMed ID: 24089159
[TBL] [Abstract][Full Text] [Related]
24. Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study.
Komaba H; Fukagawa M;
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S44-9. PubMed ID: 19032527
[TBL] [Abstract][Full Text] [Related]
25. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
[TBL] [Abstract][Full Text] [Related]
26. Active vitamin D analogs, maxacalcitol and alfacalcidol, as maintenance therapy for mild secondary hyperparathyroidism in hemodialysis patients - a randomized study.
Honda H; Koiwa F; Ogata H; Shishido K; Sekiguchi T; Michihata T; Ogawa H; Mukai M; Takahashi K; Suzuki R; Kino K; Kato K; Yamamoto K; Kinugasa E; Akizawa T
Int J Clin Pharmacol Ther; 2014 May; 52(5):360-8. PubMed ID: 24569127
[TBL] [Abstract][Full Text] [Related]
27. The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.
Bucharles SGE; Barreto FC; Riella MC
J Bras Nefrol; 2019 Jul; 41(3):336-344. PubMed ID: 31419274
[TBL] [Abstract][Full Text] [Related]
28. Management of serum calcium reductions among patients on hemodialysis following cinacalcet initiation.
Brunelli SM; Dluzniewski PJ; Cooper K; Do TP; Sibbel S; Bradbury BD
Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1058-67. PubMed ID: 26238994
[TBL] [Abstract][Full Text] [Related]
29. Long-Term Use of Cinacalcet in Kidney Transplant Recipients With Hypercalcemic Secondary Hyperparathyroidism: A Single-Center Prospective Study.
Zavvos V; Fyssa L; Papasotiriou M; Papachristou E; Ntrinias T; Savvidaki E; Goumenos DS
Exp Clin Transplant; 2018 Jun; 16(3):287-293. PubMed ID: 29108515
[TBL] [Abstract][Full Text] [Related]
30. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.
Messa P; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Wilkie M; Zani VJ; Molemans B; Carter D; Locatelli F
Clin J Am Soc Nephrol; 2008 Jan; 3(1):36-45. PubMed ID: 18178780
[TBL] [Abstract][Full Text] [Related]
31. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.
Fishbane S; Shapiro WB; Corry DB; Vicks SL; Roppolo M; Rappaport K; Ling X; Goodman WG; Turner S; Charytan C
Clin J Am Soc Nephrol; 2008 Nov; 3(6):1718-25. PubMed ID: 18945995
[TBL] [Abstract][Full Text] [Related]
32. Role of cinacalcet in management of mineral bone disorder in chronic kidney disease (control of calcium, phosphorus and parathyroid hormone).
Tahara H
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S27-33. PubMed ID: 19032524
[TBL] [Abstract][Full Text] [Related]
33. Activation of the Calcium Receptor by Calcimimetic Agents Is Preserved Despite Modest Attenuating Effects of Hyperphosphatemia.
Goodman WG; Ward DT; Martin KJ; Drayer D; Moore C; Xu J; Lai J; Chon Y; Nemeth EF
J Am Soc Nephrol; 2022 Jan; 33(1):201-212. PubMed ID: 34732508
[TBL] [Abstract][Full Text] [Related]
34. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
[TBL] [Abstract][Full Text] [Related]
35. Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism.
Kuczera P; Adamczak M; Więcek A
BMC Nephrol; 2016 Nov; 17(1):176. PubMed ID: 27846800
[TBL] [Abstract][Full Text] [Related]
36. [Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients in real-world clinical practice - the ECHO observational study: French experience].
Ureña P; Fouque D; Brunet P; Touam M; Réglier JC
Nephrol Ther; 2012 Dec; 8(7):527-33. PubMed ID: 23018042
[TBL] [Abstract][Full Text] [Related]
37. The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
Parfrey PS; Drüeke TB; Block GA; Correa-Rotter R; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Kubo Y; Dehmel B; Goodman WG; Chertow GM;
Clin J Am Soc Nephrol; 2015 May; 10(5):791-9. PubMed ID: 25710802
[TBL] [Abstract][Full Text] [Related]
38. [Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level].
Mercadal Orfila G; Blasco Mascaró I
Farm Hosp; 2012; 36(1):11-5. PubMed ID: 21514862
[TBL] [Abstract][Full Text] [Related]
39. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
40. Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006.
St Peter WL; Li Q; Liu J; Persky M; Nieman K; Arko C; Block GA
Clin J Am Soc Nephrol; 2009 Feb; 4(2):354-60. PubMed ID: 19129318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
